Metformina Pharmakern (Metformin Hydrochloride)

Metformin lowers blood sugar primarily by activating AMP‑activated protein kinase, which suppresses hepatic glucose production. It also enhances peripheral uptake of glucose in muscle and fat tissues and reduces intestinal glucose absorption, thereby improving overall insulin sensitivity without stimulating insulin release.

The exact dosage of Metformina Pharmakern is determined by the prescribing healthcare professional based on the individual’s renal function, glycemic targets, and tolerance. The prescriber will select an appropriate starting dose and may adjust it during follow‑up visits.

Metformin crosses the placenta and is classified as a pregnancy category where benefits must outweigh potential risks. It may be continued in pregnancy if deemed necessary by the obstetrician. Limited data exist for breastfeeding, and the decision should be made by the clinician after evaluating infant exposure.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Metformin belongs to the biguanide class and differs from sulfonylureas, which stimulate insulin release and carry a higher risk of hypoglycemia. Metformin does not cause hypoglycemia when used alone, has a favorable weight profile, and is generally considered first‑line therapy for type 2 diabetes.

Metformina Pharmakern should be stored at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

The medication is taken orally, usually with meals to reduce gastrointestinal discomfort. Tablets should be swallowed whole with a full glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider and not crush or split extended‑release formulations unless instructed.

The most critical adverse effect is lactic acidosis, a rare but potentially fatal condition that can occur in patients with severe renal impairment, hepatic disease, or excessive alcohol intake. Other serious concerns include severe skin reactions such as Stevens‑Johnson syndrome and marked liver enzyme elevations.

Metformina Pharmakern is contraindicated in patients with known hypersensitivity to metformin, severe renal impairment (eGFR < 30 mL/min/1.73 m²), acute or chronic metabolic acidosis, and in those receiving radiographic contrast studies that may affect renal function without appropriate precautions.